Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma

被引：0
|
作者：
Larrosa, Crstina
Simao Rafael, Margarida
Pablo Munoz, Juan
Gorostegui, Maite
Castaneda Heredia, Alicia
Garraus, Moira
Mora, Jaume
机构：
[1] Hosp St Joan de Deu, Barcelona, Spain
[2] Hosp St Joan de Deu, Pediat Canc Ctr Barcelona, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10037
引用
收藏
页数：1
相关论文
共 50 条
  • [31] New treatments, new challenges: nephrotoxicity associated to naxitamab in patients with high-risk neuroblastoma
    Sancho, Pedro Arango
    Rodriguez, Ana Cristina Aguilar
    Espinoza, Yarima Lopez
    Marin, Emma Fortes
    Perez, Juan Pablo Munoz
    Obanos, Maite Gorostegui
    Banos, Yolanda Calzada
    Baez, Victor Alfonso Lopez
    Moreno, Marta Jimenez
    Sampera, Elena Codina
    Aris, Alvaro Madrid
    Mora, Jaume
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [32] PATTERN OF RELAPSE IN HIGH-RISK NEUROBLASTOMA (HR-NB) PATIENTS CONSOLIDATED WITH NAXITAMAB
    Rodriguez, Amalia Varo
    Vallejo, Elena Soques
    Gorostegui, Maite
    Zallo, Laura Andres
    Munoz Perez, Juan Pablo
    Heredia, Alicia Castaneda
    Mora, Jaume
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S231 - S231
  • [33] Immunotherapy with ch14.18/CHO in combination with IL2 is active and effective in high-risk relapsed/refractory neuroblastoma patients
    Lode, Holger N.
    Valteau-Couanet, Dominique
    Garaventa, Alberto
    Gray, Juliet
    Castel, Victoria
    Yaniv, Isaac
    Siebert, Nikolai
    Jensen, Christian
    Endres, Stefanie
    Pill, Lena
    Eger, Christin
    Seidel, Diana
    Juettner, Madlen
    Kietz, Silke
    Ehlert, Karoline
    Janzek, Evelyne
    Manzitti, Carla
    Mueller, Ina
    Loibner, Hans
    Ladenstein, Ruth
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [34] Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/refractory high-risk neuroblastoma (HR-NB).
    Mora, Jaume
    Chan, Godfrey Chi-Fung
    Morgenstern, Daniel A.
    Nysom, Karsten
    Bear, Melissa K.
    Dalby, Lene Worsaae
    Lisby, Steen
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Outcome in patients with refractory high-risk neuroblastoma.
    Siddiqui, Amir Bari
    Oppong, Akosua
    Yuan, Cindy
    Gao, Guimin
    Bagatell, Rochelle
    Berg, Katherine
    Sokol, Elizabeth
    MacQuarrie, Kyle
    Pinto, Navin R.
    Gollapudi, Anurekha
    Mody, Rajen
    Wolfe, Ian
    Shusterman, Suzanne
    Foster, Jennifer
    Smith, Valeria
    Cohn, Susan Lerner
    Desai, Ami Vijay
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
    Quintarelli, Concetta
    del Bufalo, Francesca
    Locatelli, Franco
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (24): : 2303 - 2304
  • [37] GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
    Del Bufalo, Francesca
    De Angelis, Biagio
    Caruana, Ignazio
    Del Baldo, Giada
    De Ioris, Maria A.
    Serra, Annalisa
    Mastronuzzi, Angela
    Cefalo, Maria G.
    Pagliara, Daria
    Amicucci, Matteo
    Li Pira, Giuseppina
    Leone, Giovanna
    Bertaina, Valentina
    Sinibaldi, Matilde
    Di Cecca, Stefano
    Guercio, Marika
    Abbaszadeh, Zeinab
    Iaffaldano, Laura
    Gunetti, Monica
    Iacovelli, Stefano
    Bugianesi, Rossana
    Macchia, Stefania
    Algeri, Mattia
    Merli, Pietro
    Galaverna, Federica
    Abbas, Rachid
    Garganese, Maria C.
    Villani, Maria F.
    Colafati, Giovanna S.
    Bonetti, Federico
    Rabusin, Marco
    Perruccio, Katia
    Folsi, Veronica
    Quintarelli, Concetta
    Locatelli, Franco
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (14): : 1284 - 1295
  • [38] Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
    Mora, Jaume
    Castaneda, Alicia
    Colombo, Maria Cecilia
    Gorostegui, Maite
    Gomez, Fernando
    Mane, Salvador
    Santa-Maria, Vicente
    Garraus, Moira
    Macias, Napoleon
    Perez-Jaume, Sara
    Munoz, Oscar
    Munoz, Juan Pablo
    Barber, Ignasi
    Sunol, Mariona
    CANCERS, 2021, 13 (06) : 1 - 18
  • [39] Temozolomide phase II study in children with relapsing refractory high-risk neuroblastoma.
    Rubie, H.
    Chishlom, J.
    Defachelles, A.
    Morland, B.
    Munzer, C.
    Couanet, D. Valteau
    Hargrave, D.
    Bergeron, C.
    Coze, C.
    Djafari, L.
    Vassal, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 505S - 505S
  • [40] Temozolomide as a Single Agent or in Combination for Patients with High Risk Refractory or Relapsed Neuroblastoma: Excellent Tolerance and Sustained Disease Responses
    Metayer, L.
    Annereau, M.
    Abbas, R.
    Hinterlang, M.
    Schleiermacher, G.
    Defachelles, A. S.
    Pasqualini, C.
    Berlanga, P.
    Vassal, G.
    Valteau-Couanet, D.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S33 - S34
12345